One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations
Susanne Malander(Lund University), Åke Borg, Mef Nilbert(University of Copenhagen), Anna Måsbäck(Skåne University Hospital), Ulf Kristoffersson, Håkan Olsson(Nokia (Finland)), Niklas Loman(Lund University), Mona Ridderheim(Lund University)
Cited by 92
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Identification of FAP Locus Genes from Chromosome 5q21
|Science|1991|2.4k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k